179 related articles for article (PubMed ID: 11314771)
1. Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice.
Fredriksson A; Danysz W; Quack G; Archer T
J Neural Transm (Vienna); 2001; 108(2):167-87. PubMed ID: 11314771
[TBL] [Abstract][Full Text] [Related]
2. Functional alteration by NMDA antagonist: effects of L-Dopa, neuroleptics drug and postnatal administration.
Fredriksson A; Archer T
Amino Acids; 2002; 23(1-3):111-32. PubMed ID: 12373526
[TBL] [Abstract][Full Text] [Related]
3. Tolerance to a suprathreshold dose of L-Dopa in MPTP mice: effects of glutamate antagonists.
Fredriksson A; Palomo T; Chase T; Archer T
J Neural Transm (Vienna); 1999; 106(3-4):283-300. PubMed ID: 10392537
[TBL] [Abstract][Full Text] [Related]
4. Effects of co-administration of anticonvulsant and putative anticonvulsive agents and sub/suprathreshold doses of L-dopa upon motor behaviour of MPTP-treated mice.
Fredriksson A; Palomo T; Archer T
J Neural Transm (Vienna); 1999; 106(9-10):889-909. PubMed ID: 10599871
[TBL] [Abstract][Full Text] [Related]
5. Effect of postnatal iron administration on MPTP-induced behavioral deficits and neurotoxicity: behavioral enhancement by L-Dopa-MK-801 co-administration.
Fredriksson A; Archer T
Behav Brain Res; 2003 Feb; 139(1-2):31-46. PubMed ID: 12642174
[TBL] [Abstract][Full Text] [Related]
6. Synergistic interactions between NMDA-antagonists and L-dopa on activity in MPTP-treated mice.
Fredriksson A; Gentsch C; Archer T
J Neural Transm Gen Sect; 1994; 97(3):197-209. PubMed ID: 7873129
[TBL] [Abstract][Full Text] [Related]
7. Restorative effects of glutamate antagonists in experimental parkinsonism.
Archer T; Palomo T; Fredriksson A
Amino Acids; 2002; 23(1-3):71-85. PubMed ID: 12373521
[TBL] [Abstract][Full Text] [Related]
8. Effects of MAO inhibitors upon MPTP mice chronically treated with suprathreshold doses of L-dopa.
Fredriksson A; Palomo T; Archer T
Behav Pharmacol; 2000 Nov; 11(7-8):571-81. PubMed ID: 11198128
[TBL] [Abstract][Full Text] [Related]
9. An antihypokinesic action of alpha2-adrenoceptors upon MPTP-induced behaviour deficits in mice.
Archer T; Fredriksson A
J Neural Transm (Vienna); 2003 Feb; 110(2):183-200. PubMed ID: 12589577
[TBL] [Abstract][Full Text] [Related]
10. Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice.
Fredriksson A; Archer T
J Neural Transm Gen Sect; 1995; 102(1):19-34. PubMed ID: 8785021
[TBL] [Abstract][Full Text] [Related]
11. Memantine, amantadine, and L-deprenyl potentiate the action of L-dopa in monoamine-depleted rats.
Skuza G; Rogoz Z; Quack G; Danysz W
J Neural Transm Gen Sect; 1994; 98(1):57-67. PubMed ID: 7710739
[TBL] [Abstract][Full Text] [Related]
12. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
[TBL] [Abstract][Full Text] [Related]
13. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
Smith LA; Jackson MJ; Hansard MJ; Maratos E; Jenner P
Mov Disord; 2003 May; 18(5):487-95. PubMed ID: 12722161
[TBL] [Abstract][Full Text] [Related]
14. Restoration and putative protection in Parkinsonism.
Archer T; Fredriksson A
Neurotox Res; 2000; 2(2-3):251-92. PubMed ID: 16787845
[TBL] [Abstract][Full Text] [Related]
15. MPTP-induced hypoactivity in mice: reversal by L-dopa.
Fredriksson A; Plaznik A; Sundström E; Jonsson G; Archer T
Pharmacol Toxicol; 1990 Oct; 67(4):295-301. PubMed ID: 2077520
[TBL] [Abstract][Full Text] [Related]
16. Modifications of the behavioral profile of non-competitive NMDA receptor antagonists, memantine, amantadine and (+)MK-801 after chronic administration.
Hesselink MB; Smolders H; De Boer AG; Breimer DD; Danysz W
Behav Pharmacol; 1999 Feb; 10(1):85-98. PubMed ID: 10780305
[TBL] [Abstract][Full Text] [Related]
17. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Tronci E; Fidalgo C; Zianni E; Collu M; Stancampiano R; Morelli M; Gardoni F; Carta M
Neuroscience; 2014 Apr; 265():245-52. PubMed ID: 24486947
[TBL] [Abstract][Full Text] [Related]
18. Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: Paradoxical inhibition is relieved by D(2)/D(3) receptor blockade.
Viaro R; Marti M; Morari M
Exp Neurol; 2010 Jun; 223(2):473-84. PubMed ID: 20122926
[TBL] [Abstract][Full Text] [Related]
19. Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice.
Zaitone SA; Hammad LN; Farag NE
Pharmacol Rep; 2013; 65(5):1213-26. PubMed ID: 24399717
[TBL] [Abstract][Full Text] [Related]
20. Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys.
Hadj Tahar A; Ekesbo A; Grégoire L; Bangassoro E; Svensson KA; Tedroff J; Bédard PJ
Eur J Pharmacol; 2001 Feb; 412(3):247-54. PubMed ID: 11166288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
